These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11358679)

  • 41. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The prevalence and severity of microvascular complications in pancreatic diabetes and IDDM.
    Levitt NS; Adams G; Salmon J; Marks IN; Musson G; Swanepoel C; Levy M; Byrne MJ
    Diabetes Care; 1995 Jul; 18(7):971-4. PubMed ID: 7555558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The progression of retinopathy over 2 years: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study.
    Lloyd CE; Klein R; Maser RE; Kuller LH; Becker DJ; Orchard TJ
    J Diabetes Complications; 1995; 9(3):140-8. PubMed ID: 7548977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Kastelein JJ; Akdim F; Stroes ES; Zwinderman AH; Bots ML; Stalenhoef AF; Visseren FL; Sijbrands EJ; Trip MD; Stein EA; Gaudet D; Duivenvoorden R; Veltri EP; Marais AD; de Groot E;
    N Engl J Med; 2008 Apr; 358(14):1431-43. PubMed ID: 18376000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood.
    Olsen BS; Sjølie A; Hougaard P; Johannesen J; Borch-Johnsen K; Marinelli K; Thorsteinsson B; Pramming S; Mortensen HB
    J Diabetes Complications; 2000; 14(6):295-300. PubMed ID: 11120452
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients.
    Schalkwijk CG; Chaturvedi N; Twaafhoven H; van Hinsbergh VW; Stehouwer CD;
    Eur J Clin Invest; 2002 Jul; 32(7):500-6. PubMed ID: 12153550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
    Bestehorn HP; Rensing UF; Roskamm H; Betz P; Benesch L; Schemeitat K; Blümchen G; Claus J; Mathes P; Kappenberger L; Wieland H; Neiss A
    Eur Heart J; 1997 Feb; 18(2):226-34. PubMed ID: 9043838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria.
    Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; Raffaele J; Tsalamandris C
    Am J Kidney Dis; 2001 May; 37(5):890-9. PubMed ID: 11325669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blood pressure and microvascular complications in type 1 (insulin dependent) diabetic patients without hypertension.
    Le Floch JP; Christin S; Bertherat J; Perlemuter L; Hazard J
    Diabete Metab; 1990; 16(1):26-9. PubMed ID: 2332094
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
    Shichiri M; Kishikawa H; Ohkubo Y; Wake N
    Diabetes Care; 2000 Apr; 23 Suppl 2():B21-9. PubMed ID: 10860187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
    Bolton WK; Cattran DC; Williams ME; Adler SG; Appel GB; Cartwright K; Foiles PG; Freedman BI; Raskin P; Ratner RE; Spinowitz BS; Whittier FC; Wuerth JP;
    Am J Nephrol; 2004; 24(1):32-40. PubMed ID: 14685005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvement in endothelial dysfunction with LDL cholesterol level < 80 mg/dl in type 2 diabetic patients.
    Sheu WH; Chen YT; Lee WJ
    Diabetes Care; 2001 Aug; 24(8):1499-501. PubMed ID: 11473096
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
    Burton JR; Teo KK; Buller CE; Plante S; Catellier D; Tymchak W; Taylor D; Dzavik V; Montague TJ;
    Can J Cardiol; 2003 Apr; 19(5):487-91. PubMed ID: 12717482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
    Bang CN; Greve AM; La Cour M; Boman K; Gohlke-Bärwolf C; Ray S; Pedersen T; Rossebø A; Okin PM; Devereux RB; Wachtell K
    Am J Cardiol; 2015 Dec; 116(12):1840-4. PubMed ID: 26602073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L; Rossing P; Jensen C; Hansen BV; Parving HH
    Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
    Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
    Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
    Rossebø AB; Pedersen TR; Allen C; Boman K; Chambers J; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi VA; Malbecq W; Nienaber C; Ray S; Skjaerpe T; Wachtell K; Willenheimer R
    Am J Cardiol; 2007 Apr; 99(7):970-3. PubMed ID: 17398194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. No effect of unfractioned or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy.
    Myrup B; Jensen T; Gram J; Kluft C; Jespersen J; Deckert T
    Diabetes Care; 1997 Oct; 20(10):1615-9. PubMed ID: 9314645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.